Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea

Chey, William Y.; Jin, H.; Lee, Munho; Sun, Sungwu; Lee, Kaeyol

doi:10.1111/j.1572-0241.2000.02770.x

Cited by 44 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9][10][11]21 However, repeated exposure to low doses of a dietary antigen might lead to a process of oral tolerance. 22,23 Therefore, in the present work, we assessed the effectiveness of a shorter exposure period to high doses of oral OVA in the induction of IBS-like colonic motor alterations.…”

Section: Discussionmentioning

confidence: 99%

“…These OVA-mediated changes are reminiscent of those observed in IBS patients and in animal models of the disease. [7][8][9][10][11] Gut commensal microbiota (GCM) has been implicated in the maintenance of the normal gastrointestinal hyporesponsive state to food antigens. For instance, results obtained in studies in infants with food allergy show a disturbed balance between beneficial and potentially harmful bacteria in the large intestine and that supplementation with probiotics appears to alleviate the allergic inflammation.…”

Section: -5mentioning

confidence: 99%

See 1 more Smart Citation

Lipopolysaccharides Facilitate Colonic Motor Alterations Associated to the Sensitization to a Luminal Antigen in Rats

Jardí

Aguilera

Vergara

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/Aims Enteric dysbiosis is a risk factor for dietary proteins-associated intestinal alterations, contributing to the development of food allergies and the symptomatology of functional gastrointestinal disorders, mainly irritable bowel syndrome (IBS). We explored if a dysbiotic-like state, simulated by intraperitoneal administration of bacterial lipopolysaccharides (LPS), facilitates the sensitization to a luminal antigen, ovalbumin (OVA), in rats. Methods Rats were exposed to oral OVA for 1 week, alone or with LPS. Thereafter, colonic histology, goblet cell density, mucosal eosinophils and mucosal mast cell (MMC) and connective tissue mast cell (CTMC) were evaluated. Colonic expression (real-time quantitative polymerase chain reaction) of interleukins, IFN-α1 and integrins was assessed to determine local immune responses. Luminal and wall adhered microbiota were characterized by fluorescence in situ hybridization. Colonic contractility (in vitro) served to assess functional changes associated to OVA and/or LPS. Results Neither OVA nor LPS, alone or combined, lead to structural alterations, except for a reduced goblet cell density in OVA-LPS-treated rats. MMC density was unaffected, while CTMC counts increased within the submucosa of OVA-LPS-treated animals. Marginal immune activation (IFN-α1 up-regulation) was observed in OVA-LPS-treated rats. LPS induced a dysbiotic-like state characterized by decreased luminal bacterial counts, with a specific loss of clostridia. LPS facilitated Clostridium spp. wall adherence, an effect prevented by OVA. Colonic contractility was altered in OVA-LPS-treated animals, showing increased basal activity and enhanced motor responses to OVA. Conclusions Changes in gut microbiota and/or direct effects of LPS might enhance/facilitate local neuroimmune responses to food antigens leading to motor alterations similar to those observed in IBS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: -5mentioning

confidence: 99%

Lipopolysaccharides Facilitate Colonic Motor Alterations Associated to the Sensitization to a Luminal Antigen in Rats

Jardí

Aguilera

Vergara

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7] However, persons were enrolled from the general population with a predicted FBD probability of more than 75% (score ≥ 629) based on a previously validated BDQ questionnaire. 31 The BDQ was extensively tested and found to be reliable (, 0.81) with adequate content and predictive and construct validity.…”

Section: Fodmapsmentioning

confidence: 99%

“…These individuals are known to have altered GI environment such as motility, 3 increased fermentation, 4 visceral hypersensitivity, 5 abnormal gas transit, 6 and dysbiosis of the GI microbiota. 7 Exclusion of fermentable substrates from the diet has attracted some interest lately, as a potential treatment of IBS symptoms.…”

Section: Introductionmentioning

confidence: 99%

Effect of a prebiotic galactooligosaccharide mixture (B‐GOS®) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence

Vulevic

Tzortzis

Juric

et al. 2018

Neurogastroenterology Motil

View full text Add to dashboard Cite

BackgroundPrebiotics exert beneficial effects upon gastrointestinal (GI) environment, but this is not always accompanied with a positive effect on GI symptoms. B‐GOS® is a prebiotic with high selectivity toward bifidobacteria and a variety of other beneficial effects in humans. Here, we investigated its effect on GI symptoms in adults who suffer with bloating, abdominal pain, and flatulence.MethodsIn a double‐blind, placebo‐controlled, crossover study, 83 subjects from the general population who presented with GI symptoms during screening period and had a predicted probability of functional bowel disorder of more than 75% were randomized to receive either a placebo or the B‐GOS® treatment (2.75 g/d). Subjects were screened for the presence of GI symptoms for 1 week, they consumed the treatments for 2 weeks, and then went through a 2‐week washout period, before switching to the other treatment for the final 2 weeks. GI symptoms, bowel movements, and stool consistency were assessed in daily and weekly questionnaires. Quality of life was assessed weekly and depression and anxiety at the end of each treatment period.ResultsB‐GOS® resulted in significantly (P < 0.001) lower scores for bloating, flatulence, and abdominal pain both from baseline and placebo at the end of first week. The effect was sustained at the end of second week. It had no effect on the number of bowel movements, consistency of stools, quality of life, or mood throughout the study.ConclusionResults suggest that B‐GOS® could possibly be used in the management of bloating, flatulence, or abdominal pain and warrant further investigation.

show abstract

“…In IBS, diarrhea can occur from multiple colonic mechanisms including increased HAPCs, increased gastrocolic motility or rectal hypersensitivity. 5 Abdominal pain in IBS may be associated with HAPCs. 6 In healthy persons, the Migrating Motor Complex (MMC) repeats every 2 hours in small Bowel.…”

Section: Introductionmentioning

confidence: 99%

A comparative study of mebeverine and synbiotic combination in patients with diarrhoea predominant Irritable Bowel Syndrome in a Medical College in South India

Sujatha

Dhanasekaran

Qadri

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea

Cited by 44 publications

References 0 publications

Lipopolysaccharides Facilitate Colonic Motor Alterations Associated to the Sensitization to a Luminal Antigen in Rats

Lipopolysaccharides Facilitate Colonic Motor Alterations Associated to the Sensitization to a Luminal Antigen in Rats

Effect of a prebiotic galactooligosaccharide mixture (B‐GOS®) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence

A comparative study of mebeverine and synbiotic combination in patients with diarrhoea predominant Irritable Bowel Syndrome in a Medical College in South India

Contact Info

Product

Resources

About